Dynamics of β-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of β-Amyloid Precursor Protein Transgenic Mice Treated with a γ-Secretase Inhibitor

Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice

Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210

Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160

Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice

Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447

RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain

Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,426

Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier

Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413

BACE1 is the major β-secretase for generation of Aβ peptides by neurons

Cai, H., Wang, Y., McCarthy, D. B., Wen, H., Borchelt, D., Price, D. L., & Wong, P. C. (2001) · Nature Neuroscience · doi:10.1038/85064 · Cited by 1,087

Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease

Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053 · cited 1×

Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease

Lim, G. P., Yang, F., Chu, T., Chen, P., Beech, W. K., Teter, B., Tran, T., Ubeda, O. J., Ashe, K. H., Frautschy, S. A., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-15-05709.2000 · Cited by 876

Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain

Dovey, H. F., John, V., Anderson, J. P., Chen, L. Z., Andrieu, P. D. S. I., Fang, L. Y., Freedman, S. B., Folmer, B., Goldbach, E. G., Holsztynska, E. J., et al. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00012.x · Cited by 870

T-cell development and the CD4–CD8 lineage decision

Germain, R. N. (2002) · Nature reviews. Immunology · doi:10.1038/nri798 · Cited by 813

Amyloid Precursor Protein Processing and Alzheimer's Disease

O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061

Protein aggregation diseases: pathogenicity and therapeutic perspectives

Aguzzi, A., & O’Connor, T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3050 · Cited by 766

Alzheimer's Disease: From Pathology to Therapeutic Approaches

Jakob‐Roetne, R., & Jacobsen, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802808 · Cited by 626

Using Graphene Oxide High Near‐Infrared Absorbance for Photothermal Treatment of Alzheimer's Disease

Li, M., Yang, X., Ren, J., Qu, K., & Qu, X. (2012) · Advanced Materials · doi:10.1002/adma.201104864 · Cited by 535

Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model

Hirata-Fukae, C., Li, H.-F., Hoe, H.-S., Gray, A. J., Minami, S. S., Hamada, K., Niikura, T., Hua, F., Tsukagoshi-Nagai, H., Horikoshi-Sakuraba, Y., et al. (2008) · Brain Research · doi:10.1016/j.brainres.2008.03.079 · Cited by 284

γ-Secretase inhibitors and modulators

Golde, T. E., Koo, E. H., Felsenstein, K. M., Osborne, B. A., & Miele, L. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.06.005 · Cited by 275

Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics

Masters, C. L., Cappai, R., Barnham, K. J., & Villemagne, V. L. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03989.x · Cited by 242

Persistent Amyloidosis following Suppression of Aβ Production in a Transgenic Model of Alzheimer Disease

Jankowsky, J. L., Slunt, H. H., Gonzales, V., Savonenko, A. V., Wen, J. C., Jenkins, N. A., Copeland, N. G., Younkin, L. H., Lester, H. A., Younkin, S. G., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020355 · Cited by 237

Cerebrospinal Fluid Biomarkers and Rate of Cognitive Decline in Very Mild Dementia of the Alzheimer Type

Snider, B. J., Fagan, A. M., Roe, C. M., Shah, A. R., Grant, E., Xiong, C., Morris, J. C., & Holtzman, D. M. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.55 · Cited by 229

A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease

Aisen, P. S. S., Saumier, D., Briand, R., Laurin, J., Gervais, F., Tremblay, P., & Garceau, D. (2006) · Neurology · doi:10.1212/01.wnl.0000244346.08950.64 · Cited by 198

Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics

Goure, W. F., Krafft, G. A., Jerecic, J., & Hefti, F. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt272 · Cited by 190

Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor

Gillman, K. W., Starrett, J. E., Parker, M. F., Xie, K. M., Bronson, J. J., Marcin, L. R., McElhone, K. E., Bergstrom, C. P., Mate, R. A., Williams, R. D., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml1000239 · Cited by 185

C-terminal Fragment of Presenilin Is the Molecular Target of a Dipeptidic γ-Secretase-specific Inhibitor DAPT (N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-Butyl Ester)

Morohashi, Y., Kan, T., Tominari, Y., Fuwa, H., Okamura, Y., Watanabe, N., Sato, C., Natsugari, H., Fukuyama, T., Iwatsubo, T., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513012200 · Cited by 184

Aβ42 Neurotoxicity Is Mediated by Ongoing Nucleated Polymerization Process Rather than by Discrete Aβ42 Species

Jan, A., Adolfsson, O., Allaman, I., Buccarello, A. L., Magistretti, P. J., Pfeifer, A., Muhs, A., & Lashuel, H. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.172411 · Cited by 179

Disease‐modifying therapies in Alzheimer's disease

Salloway, S., Mintzer, J. E., Weiner, M., & Cummings, J. L. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2007.10.001 · Cited by 163

Begacestat (GSI-953): A Novel, Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein γ-Secretase for the Treatment of Alzheimer's Disease

Martone, R., Zhou, H., Atchison, K., Comery, T., Xu, J. Z., Huang, X.-Y., Gong, X., Jin, M., Kreft, A., Harrison, B., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.152975 · Cited by 163

Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis

Castellano, J. M., Deane, R., Gottesdiener, A. J., Verghese, P. B., Stewart, F. R., West, T., Paoletti, A. C., Kasper, T. R., DeMattos, R. B., Zlokovic, B. V., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206446109 · Cited by 154

Drug development for Alzheimer's disease: where are we now and where are we headed?

Sabbagh, M. N. (2009) · ˜The œAmerican journal of geriatric pharmacotherapy · doi:10.1016/j.amjopharm.2009.06.003 · Cited by 147

Secretase inhibitors and modulators for Alzheimer’s disease treatment

Tomita, T. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.24 · Cited by 148

Differences in amyloid-β clearance across mouse and human blood–brain barrier models: Kinetic analysis and mechanistic modeling

Qosa, H., Abuasal, B. S., Romero, I. A., Weksler, B., Couraud, P.-O., Keller, J. N., & Kaddoumi, A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.01.023 · Cited by 146

Inhibition and Modulation of γ-Secretase for Alzheimer's Disease

Wolfe, M. S. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.010 · Cited by 146

Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the A amyloid pathway

Masters, C. L., & Beyreuther, K. (2006) · Brain · doi:10.1093/brain/awl251 · Cited by 145

Parenchymal and vascular Aβ‐deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease

Thal, D. R., Griffin, W. S. T., & Braak, H. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00411.x · Cited by 134

Concentration-Dependent Modulation of Amyloid-β in Vivo and in Vitro Using the γ-Secretase Inhibitor, LY-450139

Lanz, T. A., Karmilowicz, M. J., Wood, K. M., Pozdnyakov, N., Du, P., Piotrowski, M. A., Brown, T. M., Nolan, C. E., Richter, K. E. G., Finley, J. E., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110700 · Cited by 130

Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease

Hey, J. A., Yu, Y., Versavel, M., Abushakra, S. R., Kočiš, P., Power, A., Kaplan, P. L., Amedio, J. C., & Tolar, M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0608-3 · Cited by 132

??-Secretase Inhibitors for Alzheimer??s Disease

Barten, D. M., Meredith, J. E., Zaczek, R. C., Houston, J. G., & Albright, C. F. (2006) · Drugs in R&D · doi:10.2165/00126839-200607020-00003 · Cited by 129

Neuronal death in Alzheimer’s disease and therapeutic opportunities

Donev, R., Kolev, M. V., Millet, B., & Thome, J. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00889.x · Cited by 126

Treatment Strategies Targeting Amyloid -ProteinPreprint

Schenk, D., Basi, G. S., & Pangalos, M. N. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006387 · Cited by 131

Alzhemed: A Potential Treatment for Alzheimers Disease

Aisen, P. S. S., Gauthier, S. G., Vellas, B. J., Briand, R., Saumier, D., Laurin, J., & Garceau, D. (2007) · Current Alzheimer Research · doi:10.2174/156720507781788882 · Cited by 116

Discovery of Begacestat, a Notch-1-Sparing γ-Secretase Inhibitor for the Treatment of Alzheimer’s Disease

Mayer, S. C., Kreft, A. F., Harrison, B. L., Abou-Gharbia, M. A., Antane, M. M., Aschmies, S., Atchison, K. P., Chlenov, M. A., Cole, D. C., Comery, T. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm801252w · Cited by 111

Metabolism-Directed Design of Oxetane-Containing Arylsulfonamide Derivatives as γ-Secretase Inhibitors

Stepan, A. F., Karki, K., McDonald, W. S., Dorff, P. H., Dutra, J. K., DiRico, K. J., Won, A. C., Subramanyam, C., Efremov, I. V., O’Donnell, C. J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200893p · Cited by 109

First Demonstration of Cerebrospinal Fluid and Plasma Aβ Lowering with Oral Administration of a β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor in Nonhuman Primates

Sankaranarayanan, S., Holahan, M. A., Colussi, D. J., Crouthamel, M., Devanarayan, V., Ellis, J. D., Espeseth, A. S., Gates, A. T., Graham, S. L., Gregro, A. R., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.143628 · Cited by 107

Inhibition of ??-Secretase as a Therapeutic Intervention for Alzheimer???s Disease

Evin, G. M., Sernee, M. F., & Masters, C. L. (2006) · CNS Drugs · doi:10.2165/00023210-200620050-00002 · Cited by 106

Recent Advances in the Identification of γ-Secretase Inhibitors To Clinically Test the Aβ Oligomer Hypothesis of Alzheimer’s Disease

Kreft, A. F., Martone, R. L., & Porte, A. M. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900188z · Cited by 105

The Development of Anti-Amyloid Therapy for Alzheimer???s Disease

Aisen, P. S. S. (2005) · CNS Drugs · doi:10.2165/00023210-200519120-00002 · Cited by 103

BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild‐type mice2

Nishitomi, K., Sakaguchi, G., Horikoshi, Y., Gray, A. J., Maeda, M., Hirata‐Fukae, C., Becker, A. G., Hosono, M., Sakaguchi, I., Minami, S., et al. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04178.x · Cited by 97

Reductions in β-amyloid concentrations in vivo by the γ-secretase inhibitors BMS-289948 and BMS-299897

Anderson, J. J., Holtz, G., Baskin, P. P., Turner, M., Rowe, B. A., Wang, B., Kounnas, M. Z., Lamb, B. T., Barten, D. M., Felsenstein, K. M., et al. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.11.015 · Cited by 93

Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease

Aluise, C. D., Robinson, R. A. S., & Butterfield, D. A. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.07.008 · Cited by 94

Using Multifunctional Peptide Conjugated Au Nanorods for Monitoring β-Amyloid Aggregation and Chemo-Photothermal Treatment of Alzheimer’s Disease

Li, M., Guan, Y., Zhao, A., Ren, J., & Qu, X. (2017) · Theranostics · doi:10.7150/thno.18459 · Cited by 90

Dynamics of Aβ Turnover and Deposition in Different β-Amyloid Precursor Protein Transgenic Mouse Models Following γ-Secretase Inhibition

Abramowski, D., Wiederhold, K.-H., Furrer, U., Jaton, A.-L., Neuenschwander, A., Runser, M.-J., Danner, S., Reichwald, J., Ammaturo, D., Staab, D., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.140327 · Cited by 89

The Novel γ Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) Reduces Amyloid Plaque Deposition without Evidence of Notch-Related Pathology in the Tg2576 Mouse

Best, J. D., Smith, D. W., Reilly, M., O’Donnell, R., Lewis, H. D., Ellis, S., Wilkie, N., Rosahl, T. W., Laroque, P. A., Boussiquet-Leroux, C., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.114330 · Cited by 84

γ-Secretase in biology and medicine

Wolfe, M. S. (2009) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2008.12.011 · Cited by 85

Development of Beta-Amyloid-induced Neurodegeneration in Alzheimer's Disease and Novel Neuroprotective Strategies

Hölscher, C. (2005) · Reviews in the Neurosciences · doi:10.1515/revneuro.2005.16.3.181 · Cited by 83

Moderate Reduction of γ-Secretase Attenuates Amyloid Burden and Limits Mechanism-Based Liabilities

Li, T., Wen, H., Brayton, C. F., Laird, F. M., Ma, G., Peng, S., Placanica, L., Wu, T. C., Crain, B. J., Price, D. L., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.2152-07.2007 · Cited by 80

Sulfated Polysaccharides Promote the Assembly of Amyloid β1–42 Peptide into Stable Fibrils of Reduced Cytotoxicity

Bravo, R., Arimon, M., Valle‐Delgado, J. J., García, R., Durany, N., Castel, S., Cruz, M., Ventura, S., & Fernàndez‐Busquets, X. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709870200 · Cited by 79

Plasma and cerebrospinal fluid amyloid-β levels in late-life depression: A systematic review and meta-analysis

do Nascimento, K. K. F., Silva, K. P., Malloy‐Diniz, L. F., Butters, M. A., & Diniz, B. S. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.07.024 · Cited by 72

Studies to Investigate the in Vivo Therapeutic Window of the γ-Secretase Inhibitor N2-[(2 S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7 S)-5-methyl-6-oxo-6,7-dihydro-5 H-dibenzo[b,d]azepin-7-yl]-l-alaninamide (LY411,575) in the CRND8 Mouse

Hyde, L. A., McHugh, N. A., Chen, J., Zhang, Q., Manfra, D. J., Nomeir, A. A., Josien, H. B., Bara, T. A., Clader, J. W., Zhang, L., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.111716 · Cited by 69

γ-Secretase Inhibition and Modulation for Alzheimers Disease

Wolfe, M. S. (2008) · Current Alzheimer Research · doi:10.2174/156720508783954767 · Cited by 68

The Amyloid-β Rise and γ-Secretase Inhibitor Potency Depend on the Level of Substrate Expression

Burton, C. R., Meredith, J. E., Barten, D. M., Goldstein, M. E., Krause, C., Kieras, C. J., Sisk, L. M., Iben, L. G., Polson, C. T., Thompson, M. W., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804175200 · Cited by 62

Pharmacodynamics of Selective Inhibition of γ-Secretase by Avagacestat

Albright, C. F., Dockens, R. C., Meredith, J. E., Olson, R. E., Slemmon, R., Lentz, K. A., Wang, J.-S., Denton, R., Pilcher, G. D., Rhyne, P., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.199356 · Cited by 63

In Vivo Characterization of Aβ(40) Changes in Brain and Cerebrospinal Fluid Using the Novel γ-Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the Rat

Best, J. D., Jay, M. T., Otu, F., Churcher, I., Reilly, M., Gutierrez, P. M., Pattison, C., Harrison, T., Shearman, M. S., & Atack, J. R. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.100271 · Cited by 63

Identification of γ-Secretase Inhibitor Potency Determinants on Presenilin

Zhao, B., Yu, M., Neitzel, M. L., Marugg, J. L., Jagodzinski, J. J., Lee, M., Hu, K., Schenk, D., Yednock, T. A., & Basi, G. S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m708870200 · Cited by 61

Early-stage blocking of Notch signaling inhibits the depletion of goblet cells in dextran sodium sulfate-induced colitis in mice

Shinoda, M., Shin‐Ya, M., Naito, Y., Kishida, T., Ito, R., Suzuki, N., Yasuda, H., Sakagami, J., Imanishi, J., Kataoka, K., et al. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-010-0210-z · Cited by 61

Protease inhibitors as potential disease-modifying therapeutics for Alzheimer’s disease

Beher, D., & Graham, S. L. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.11.1385 · Cited by 61

γ-Secretase: a complex target for Alzheimer's disease

Lundkvist, J., & Näslund, J. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.10.002 · Cited by 58

The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice

Huttunen, H. J., Havas, D., Peach, C., Barren, C., Duller, S., Xia, W., Frosch, M. P., Hutter-Paier, B., Windisch, M., & Kovacs, D. M. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181e77ed9 · Cited by 54

γ-Secretase and the Intramembrane Proteolysis of Notch

Jorissen, E., & Strooper, B. D. (2010) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(10)92006-1 · Cited by 61

Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease

Basi, G. S., Hemphill, S. S., Brigham, E. F., Liao, A., Aubele, D. L., Baker, J., Barbour, R., Bova, M. P., Chen, X., Dappen, M. S., et al. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt60 · Cited by 53

Modeling an Anti-Amyloid Combination Therapy for Alzheimer’s Disease

Chow, V. W., Savonenko, A. V., Melnikova, T., Kim, H., Price, D. L., Li, T., & Wong, P. C. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000337 · Cited by 53

Pharmacodynamics and Pharmacokinetics of the γ-Secretase Inhibitor PF-3084014

Lanz, T. A., Wood, K. M., Richter, K. E. G., Nolan, C. E., Becker, S. L., Pozdnyakov, N., Martin, B., Du, P., Oborski, C., Wood, D. E., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.167379 · Cited by 50

Current therapeutic strategy in Alzheimer's disease.

Singh, S., Kushwah, A. S., Singh, R., Farswan, M., & Kaur, R. (2012) · PubMed · Cited by 47

Oligodendrocytes are a Novel Source of Amyloid Peptide Generation

Skaper, S. D., Evans, N. A., Soden, P. E., Rosin, C., Facci, L., & Richardson, J. C. (2009) · Neurochemical Research · doi:10.1007/s11064-009-0022-9 · Cited by 43

Novel therapeutics for Alzheimer's disease: an update.

Bonda, D., Lee, H. P., Lee, H., Friedlich, A. L., Perry, G. L., Zhu, X., & Smith, M. A. (2010) · PubMed · Cited by 41

The γ-secretase inhibitor 2-[(1R)-1-[(4-chlorophenyl)sulfonyl](2,5-difluorophenyl) amino]ethyl-5-fluorobenzenebutanoic acid (BMS-299897) alleviates Aβ1–42 seeding and short-term memory deficits in the Aβ25–35 mouse model of Alzheimer's disease

Meunier, J., Villard, V., Givalois, L., & Maurice, T. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.10.033 · Cited by 41

Demonstration of a common artifact in immunosorbent assays of brain extracts: Development of a solid-phase extraction protocol to enable measurement of amyloid-β from wild-type rodent brain

Lanz, T. A., & Schachter, J. B. (2006) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2006.03.023 · Cited by 40

Bridging the Gap Between Fluid Biomarkers for Alzheimer’s Disease, Model Systems, and Patients

Bjorkli, C., Sandvig, A., & Sandvig, I. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00272 · Cited by 41

P-Glycoprotein Efflux and Other Factors Limit Brain Amyloid β Reduction by β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitors in Mice

Meredith, J. E., Thompson, L. A., Toyn, J. H., Marcin, L. R., Barten, D. M., Marcinkeviciene, J. A., Kopcho, L. M., Kim, Y. J., Lin, A., Guss, V. L., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.138974 · Cited by 41

BACE and γ-Secretase Characterization and Their Sorting as Therapeutic Targets to Reduce Amyloidogenesis

Marks, N., & Berg, M. J. (2009) · Neurochemical Research · doi:10.1007/s11064-009-0054-1 · Cited by 38

Die Alzheimer‐Demenz: von der Pathologie zu therapeutischen Ansätzen

Jakob‐Roetne, R., & Jacobsen, H. (2009) · Angewandte Chemie · doi:10.1002/ange.200802808 · Cited by 41

Modulation of Amyloid β Peptide1-42 Cytotoxicity and Aggregation in Vitro by Glucose and Chondroitin Sulfate

Fernàndez‐Busquets, X., Ponce, J., Bravo, R., Arimon, M., Martiáñez, T., Gella, A., Cladera, J., & Durany, N. (2010) · Current Alzheimer Research · doi:10.2174/156720510791383787 · Cited by 38

Can insulin signaling pathways be targeted to transport Aβ out of the brain?

Vandal, M., Bourassa, P., & Calon, F. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00114 · Cited by 37

Intra- or Intercomplex Binding to the γ-Secretase Enzyme

Clarke, E. E., Churcher, I., Ellis, S., Wrigley, J. D. J., Lewis, H. D., Harrison, T., Shearman, M. S., & Beher, D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605051200 · Cited by 38

Cerebrospinal Fluid Amyloid-β (Aβ) as an Effect Biomarker for Brain Aβ Lowering Verified by Quantitative Preclinical Analyses

Lu, Y., Riddell, D. R., Hajós‐Korcsok, É., Bales, K. R., Wood, K. M., Nolan, C. E., Robshaw, A., Zhang, L., Leung, L. Y., Becker, S. L., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.192625 · Cited by 35

Scaffold of the Cyclooxygenase-2 (COX-2) Inhibitor Carprofen Provides Alzheimer γ-Secretase Modulators

Narlawar, R., Pérez‐Revuelta, B. I., Haass, C., Steiner, H., Schmidt, B., & Baumann, K. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0610200 · Cited by 36

Changing the Course of Alzheimer's Disease

Christensen, D. D. (2007) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v09n0106 · Cited by 37

Design, synthesis, and in vivo characterization of a novel series of tetralin amino imidazoles as γ-secretase inhibitors: Discovery of PF-3084014

Brodney, M. A., Auperin, D. D., Becker, S. L., Bronk, B. S., Brown, T. M., Coffman, K. J., Finley, J. E., Hicks, C. D., Karmilowicz, M. J., Lanz, T. A., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.118 · Cited by 35

Frontiers in Alzheimer’s disease therapeutics

Stone, J. G., Casadesús, G., Rothenberg, K. G., Siedlak, S. L., Wang, X., Zhu, X., Perry, G. L., Castellani, R. J., & Smith, M. A. (2010) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622310382817 · Cited by 32

Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes

Froestl, W., Muhs, A., & Pfeifer, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121537 · Cited by 31

Interaction between amyloidogenic proteins and biomembranes in protein misfolding diseases: Mechanisms, contributors, and therapy

Cheng, B., Li, Y., Ma, L., Wang, Z., Petersen, R. B., Zheng, L., Chen, Y., & Huang, K. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.02.013 · Cited by 32

Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796): A γ-secretase inhibitor with Aβ lowering activity in a transgenic mouse model of Alzheimer’s disease

Prasad, C. V. C., Zheng, M., Vig, S., Bergstrom, C. P., Smith, D. W., Gao, Q., Yeola, S. N., Polson, C. T., Corsa, J. A., Guss, V. L., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.04.082 · Cited by 32

Pharmacological Analysis of Drosophila melanogaster γ-Secretase with Respect to Differential Proteolysis of Notch and APP

Groth, C., Alvord, W. G., Quiñones, O. A., & Fortini, M. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.062471 · Cited by 31

Effects of Heparin and Enoxaparin on APP Processing and Aβ Production in Primary Cortical Neurons from Tg2576 Mice

Cui, H., Hung, A. C., Klaver, D. W., Suzuki, T., Freeman, C. G., Narkowicz, C., Jacobson, G. A., & Small, D. H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023007 · Cited by 31

Neurosecretases provide strategies to treat sporadic and familial Alzheimer disorders

Marks, N., & Berg, M. J. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.06.020 · Cited by 30

Synthesis of biotinylated photoaffinity probes based on arylsulfonamide γ-secretase inhibitors

Fuwa, H., Hiromoto, K., Takahashi, Y., Yokoshima, S., Kan, T., Fukuyama, T., Iwatsubo, T., Tomita, T., & Natsugari, H. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.05.091 · Cited by 29

γ‐secretase inhibitors for the treatment of Alzheimer's disease

Wu, W., & Zhang, L. (2009) · Drug Development Research · doi:10.1002/ddr.20288 · Cited by 28

Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling

Basak, J. M., Kim, J., Pyatkivskyy, Y., Wildsmith, K. R., Jiang, H., Parsadanian, M., Patterson, B. W., Bateman, R. J., & Holtzman, D. M. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-14 · Cited by 27

Robust Translation of γ-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects

Toyn, J. H., Boy, K. M., Raybon, J. J., Meredith, J. E., Robertson, A. S., Guss, V. L., Hoque, N., Sweeney, F., Zhuo, X., Clarke, W., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.232249 · Cited by 26

Differential effects of γ‐secretase and BACE1 inhibition on brain Aβ levels in vitro and in vivo

Elvang, A. B., Volbracht, C., Pedersen, L. Ø., Jensen, K. G., Karlsson, J.-J., Larsen, S. A., Mørk, A., Stensbøl, T. B., & Bastlund, J. F. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06215.x · Cited by 24

Qualitative and quantitative characterization of the amyloid β peptide (Aβ) population in biological matrices using an immunoprecipitation–LC/MS assay

Ford, M. J., Cantone, J. L., Polson, C. T., Toyn, J. H., Meredith, J. E., & Drexler, D. M. (2007) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2007.11.019 · Cited by 26

Signal Peptide Peptidase and γ-Secretase Share Equivalent Inhibitor Binding Pharmacology

Iben, L. G., Olson, R. E., Balanda, L. A., Jayachandra, S., Robertson, B., Hay, V., Corradi, J., Prasad, C. V. C., Zaczek, R. C., Albright, C. F., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m707002200 · Cited by 26

Probing Mechanisms and Therapeutic Potential of γ-Secretase in Alzheimer’s Disease

Wolfe, M. S. (2021) · Molecules · doi:10.3390/molecules26020388 · Cited by 28

Discovery of a novel series of Notch-sparing γ-secretase inhibitors

Kreft, A. F., Harrison, B. L., Aschmies, S., Atchison, K. P., Casebier, D. S., Cole, D. C., Diamantidis, G., Ellingboe, J. W., Hauze, D. B., Hu, Y., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.05.064 · Cited by 25

N-Substituted carbazolyloxyacetic acids modulate Alzheimer associated γ-secretase

Narlawar, R., Pérez‐Revuelta, B. I., Baumann, K., Schubenel, R., Haass, C., Steiner, H., & Schmidt, B. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.09.061 · Cited by 23

Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies

Hallé, M., Tribout-Jover, P., Lanteigne, A.-M., Boulais, J., St-Jean, J. R., Jodoin, R., Girouard, M., Constantin, F., Migneault, A., Renaud, F., et al. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.05.002 · Cited by 24

Genetic and pharmacological evidence of intraneuronal Aβ accumulation in APP transgenic mice

Philipson, O., Lannfelt, L., & Nilsson, L. N. G. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.08.009 · Cited by 21

A facile enantioselective synthesis of (S)-N-(5-chlorothiophene-2-sulfonyl)-β,β-diethylalaninol via proline-catalyzed asymmetric α-aminooxylation and α-amination of aldehyde

Rawat, V., Chouthaiwale, P. V., Chavan, V. B., Suryavanshi, G. M., & Sudalai, A. (2010) · Tetrahedron Letters · doi:10.1016/j.tetlet.2010.10.029 · Cited by 21

Novel γ-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates

Takahashi, Y., Fuwa, H., Kaneko, A., Sasaki, M., Yokoshima, S., Koizumi, H., Takebe, T., Kan, T., Iwatsubo, T., Tomita, T., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.04.025 · Cited by 21

Alzheimer's Disease

Mandell, A. M., & Green, R. C. (2011) · Wiley eBooks · doi:10.1002/9781444344110.ch1 · Cited by 22

Soluble Aβ and cognitive function in aged F-344 rats and Tg2576 mice

Lindner, M. D., Hogan, J. B., KRAUSE, R., Machet, F., Bourin, C., HODGESJR, D., Corsa, J. A., Barten, D. M., Toyn, J. H., & Stock, D. A. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.06.003 · Cited by 19

(S)-N-(5-Chlorothiophene-2-sulfonyl)-β,β-diethylalaninol a Notch-1-sparing γ-secretase inhibitor

Cole, D. C., Stock, J. R., Kreft, A. F., Antane, M. M., Aschmies, S., Atchison, K. P., Casebier, D. S., Comery, T. A., Diamantidis, G., Ellingboe, J. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.11.116 · Cited by 19

Reductions in β-amyloid concentrations in vivo by the γ-secretase inhibitors BMS-289948 and BMS-299897

Anderson, J. J., Holtz, G., Baskin, P. P., Turner, M., Rowe, B. A., Wang, B., Kounnas, M. Z., Lamb, B. T., Barten, D. M., Felsenstein, K. M., et al. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.11.015 · Cited by 93

Dynamics of Aβ Turnover and Deposition in Different β-Amyloid Precursor Protein Transgenic Mouse Models Following γ-Secretase Inhibition

Abramowski, D., Wiederhold, K.-H., Furrer, U., Jaton, A.-L., Neuenschwander, A., Runser, M.-J., Danner, S., Reichwald, J., Ammaturo, D., Staab, D., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.140327 · Cited by 89

??-Secretase Inhibitors for Alzheimer??s Disease

Barten, D. M., Meredith, J. E., Zaczek, R. C., Houston, J. G., & Albright, C. F. (2006) · Drugs in R&D · doi:10.2165/00126839-200607020-00003 · Cited by 129

Modulation of γ-Secretase Reduces β-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's Disease

Kounnas, M. Z., Danks, A. M., Cheng, S., Tyree, C. M., Ackerman, E. S., Zhang, X., Ahn, K., Nguyen, P. A. H., Comer, D., Mao, L., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.018 · Cited by 254

Acute Retention of Urine

Badenoch, A. W. (1955) · BMJ · doi:10.1136/bmj.2.4930.36 · Cited by 3